{
    "organizations": [],
    "uuid": "dfca68c2be0540a20aa3356df881c868102bd05d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/viralytics-ma-merck-co/merck-to-buy-viralytics-for-394-mln-to-boost-immuno-oncology-idUSL8N1QB2B3",
    "ord_in_thread": 0,
    "title": "Merck to buy Viralytics for $394 mln to boost immuno-oncology",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 21 (Reuters) - U.S. drugmaker Merck & Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its drug pipeline.\nMerck will pay 1.75 Australian dollars per share for the Sydney-based biotech company, which uses viruses to infect and kill cancer cells. That represents a premium of 160 percent to the average stock price over the past month. ($1 = 1.2740 Australian dollars) (Reporting by Ben Hirschler, editing by Louise Heavens)\n ",
    "published": "2018-02-21T17:26:00.000+02:00",
    "crawled": "2018-02-22T18:20:22.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "drugmaker",
        "merck",
        "co",
        "already",
        "one",
        "leader",
        "hot",
        "area",
        "cancer",
        "immunotherapy",
        "said",
        "wednesday",
        "agreed",
        "buy",
        "viralytics",
        "million",
        "australian",
        "dollar",
        "million",
        "expand",
        "drug",
        "pipeline",
        "merck",
        "pay",
        "australian",
        "dollar",
        "per",
        "share",
        "biotech",
        "company",
        "us",
        "virus",
        "infect",
        "kill",
        "cancer",
        "cell",
        "represents",
        "premium",
        "percent",
        "average",
        "stock",
        "price",
        "past",
        "month",
        "australian",
        "dollar",
        "reporting",
        "ben",
        "hirschler",
        "editing",
        "louise",
        "heaven"
    ]
}